Skip to main content

ScholarsBetaWeill Cornell Medicine

Browse About Sign in

Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research5

FiltersClear all

Status

Recruiting2
Completed3

Study type

Interventional5

Phase

Not applicable4
Phase 21

Investigator

Erica Phillips1
Holly G Prigerson1
Karen Tang1
Shoshana Rosenberg1
Sara Czaja1

Department

Medicine2
Population Health Sciences1
Psychiatry1
Radiology1

Condition

Prostatic Neoplasms52
Leukemia, Myeloid, Acute50
Breast Neoplasms43
Heart Failure34
Multiple Myeloma32

Intervention type

Behavioral4
Drug1
Other1

Sponsor type

WCM (investigator-initiated)4
Industry1

Start date

to

Has results posted1

Communication×Clear all

Showing 1–5 of 5 studiesSort:

RecruitingInterventional · Not applicableNCT06335810 ↗
Reducing Obesity Using Social Ties (ROBUST): Randomized Control Trial
Erica PhillipsPI
Intervention
Behavioral: Social Network Intervention · Behavioral: Individual Lifestyle Intervention · Other: Social Network Member
Dates
Apr 2024 – Dec 2026 (est.)

Show all 50

Show fewer

Sponsor

Weill Medical College of Cornell University

Obesity

RecruitingInterventional · Not applicableNCT07635147 ↗

Communicating Options for Advanced Breast Cancer Support and Treatment (COAST)

Shoshana RosenbergPI

Intervention: Behavioral: Decision Support Tool
Dates: Jun 2026 – Sep 2027 (est.)
Sponsor: Weill Medical College of Cornell University

Breast Cancer MetastaticAdvanced Breast CancerStage 4 Breast Cancer+1 more

CompletedInterventional · Not applicableNCT04179305 ↗

Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2

Holly G PrigersonPI

Intervention: Behavioral: Oncolo-GIST · Behavioral: Usual Care Arm
Dates: Oct 2020 – Jul 2022· Results posted
Sponsor: Weill Medical College of Cornell University

Critical IllnessOncologyCommunication

CompletedInterventional · Phase 2NCT05081245 ↗

A Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD).

Intervention: Drug: ML-004 (IR)/(ER) tablet · Drug: ML-004 Placebo
Dates: Sep 2022 – Mar 2026
Sponsor: MapLight Therapeutics, Inc

Autism Spectrum Disorder

CompletedInterventional · Not applicableNCT05143255 ↗

Developing a Communication Intervention to Help People With Memory Challenges and Their Care Partners Engage in Advance Care Planning

Intervention: Behavioral: KNOW
Dates: Dec 2024 – Feb 2026
Sponsor: Weill Medical College of Cornell University

Alzheimer DiseaseDementia